TY - JOUR
T1 - The management of dyslipidaemia in patients with type 2 diabetes mellitus receiving lipid-lowering drugs
T2 - A sub-analysis of the CEPHEUS findings
AU - Shehab, Abdullah
AU - Al-Rasadi, Khalid
AU - Arafah, Mohamed
AU - Al-Hinai, Ali T.
AU - Al Mahmeed, Wael
AU - Bhagavathula, Akshaya Srikanth
AU - Al Tamimi, Omer
AU - Al Herz, Shorook
AU - Al Anazi, Faisal
AU - Al Nemer, Khalid
AU - Metwally, Othman
AU - Alkhadra, Akram
AU - Fakhry, Mohammed
AU - Elghetany, Hossam
AU - Medani, Abdel Razak
AU - Yusufali, Afzal Hussein
AU - Al Jassim, Obaid
AU - Al Hallaq, Omar
AU - Baslaib, Fahad Omar Ahmed S.
AU - Alawadhi, Mahmoud
AU - Amin, Haitham
AU - Al-Hashmi, Khamis
AU - Oulhaj, Abderrahim
N1 - Publisher Copyright:
© 2018 Bentham Science Publishers.
PY - 2018
Y1 - 2018
N2 - Background: Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. Method: A multicentre, non-interventional survey conducted in 6 Middle Eastern countries (Bahrain, Oman, Qatar, United Arab Emirates, Kingdom of Saudi Arabia and Kuwait). Patients with T2DM (n = 3338) taking LLD treatment for ≥3 months with no dose change for ≥6 weeks were enrolled. Results: The mean age (SD) of T2DM patients was 56.6 ±10.6 years; the majority (99%) were on statin monotherapy. Only 48% of these patients achieved their low density lipoprotein cholesterol (LDL-C) goal and 67.7% of the patients had a high cardiovascular disease (CVD) risk according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Of those who achieved LDL-C goals (n=1589), approximately one-third were at very high CVD risk and the patients who had received statin monotherapy showed the highest proportion in LDL-C goal attainment, followed by those treated with fibrate monotherapy. In a multivariate logistic regression model, taking drugs daily (odds ratio, OR: 1.64, 95% CI 1.25, 2.15) and older age (OR: 1.09, 95% CI 1.01, 1.18) were significantly associated with better odds of attaining LDL-C target. In contrast, patients with higher levels of ApoA1 (OR: 0.73, 95% CI [0.67,0.79]), Metabolic Syndrome (OR: 0.64, 95% CI [0.53, 0.76]), higher CV risk (OR: 0.33, 95% CI 0.27, 0.41), those who forgot to take their medication (OR: 0.74, 95% CI 0.62,0.88) and those who stopped taking medication when cholesterol became normal (OR: 0.67, 95% CI 0.55,0.82) were significantly associated with lower odds of attaining LDL-C target. Conclusion: The results of this study highlight the suboptimal management of dyslipidaemia in T2DM patients at high and very high risk of CVD.
AB - Background: Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. Method: A multicentre, non-interventional survey conducted in 6 Middle Eastern countries (Bahrain, Oman, Qatar, United Arab Emirates, Kingdom of Saudi Arabia and Kuwait). Patients with T2DM (n = 3338) taking LLD treatment for ≥3 months with no dose change for ≥6 weeks were enrolled. Results: The mean age (SD) of T2DM patients was 56.6 ±10.6 years; the majority (99%) were on statin monotherapy. Only 48% of these patients achieved their low density lipoprotein cholesterol (LDL-C) goal and 67.7% of the patients had a high cardiovascular disease (CVD) risk according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Of those who achieved LDL-C goals (n=1589), approximately one-third were at very high CVD risk and the patients who had received statin monotherapy showed the highest proportion in LDL-C goal attainment, followed by those treated with fibrate monotherapy. In a multivariate logistic regression model, taking drugs daily (odds ratio, OR: 1.64, 95% CI 1.25, 2.15) and older age (OR: 1.09, 95% CI 1.01, 1.18) were significantly associated with better odds of attaining LDL-C target. In contrast, patients with higher levels of ApoA1 (OR: 0.73, 95% CI [0.67,0.79]), Metabolic Syndrome (OR: 0.64, 95% CI [0.53, 0.76]), higher CV risk (OR: 0.33, 95% CI 0.27, 0.41), those who forgot to take their medication (OR: 0.74, 95% CI 0.62,0.88) and those who stopped taking medication when cholesterol became normal (OR: 0.67, 95% CI 0.55,0.82) were significantly associated with lower odds of attaining LDL-C target. Conclusion: The results of this study highlight the suboptimal management of dyslipidaemia in T2DM patients at high and very high risk of CVD.
KW - Cardiovascular disease (CVD)
KW - Centralized pan-middle east survey (CEPHEUS)
KW - Dyslipidaemia
KW - Lipid-lowering drugs (LLDs)
KW - Low-density lipoprotein cholesterol (LDL-C)
KW - Middle east
KW - Type 2 diabetes mellitus (T2DM)
UR - https://www.scopus.com/pages/publications/85048874168
UR - https://www.scopus.com/pages/publications/85048874168#tab=citedBy
U2 - 10.2174/1570161115666170705153815
DO - 10.2174/1570161115666170705153815
M3 - Article
C2 - 28677510
AN - SCOPUS:85048874168
SN - 1570-1611
VL - 16
SP - 368
EP - 375
JO - Current vascular pharmacology
JF - Current vascular pharmacology
IS - 4
ER -